Association of type 2 diabetes mellitus with histopathological features of Non-metastatic breast cancer in Chinese women: a retrospective Cross-sectional study
Abstract
Breast cancer and type 2 diabetes mellitus (T2DM) are prevalent global health concerns, often sharing overlapping pathophysiological mechanisms. This study aimed to characterize the association of type 2 diabetes mellitus (T2DM) with the histopathological features of non-metastatic breast cancer in Chinese women and evaluate whether glycemic control, diabetes duration, and treatment were involved. A retrospective cross-sectional analysis was conducted on 924 patients with stage I–III ductal breast cancer, equally divided into diabetic (n = 462) and nondiabetic (n = 462) groups. Patients were stratified by fasting blood glucose (FBG) levels, use of metformin and insulin, and diabetes duration. The expression of hormone receptors estrogen and progesterone (ER, PR), human epidermal growth factor receptor 2 (HER2), Ki-67, histological grade, lymph node metastasis, and pathological tumor node metastasis (pTNM) staging were analyzed. Diabetic patients exhibited a higher incidence of triple-negative breast cancer (TNBC) and a lower incidence of HER2-positive breast cancer compared to nondiabetic patients. Poor glycemic control (FBG ≥ 10 mmol/L) was associated with a higher risk of TNBC, histological grade III disease, and lower ER-positive rates compared to those with FBG < 6.1 mmol/L. Patients taking metformin had an increased likelihood of TNBC and decreased ER-positive rates. Insulin-treated patients demonstrated a lower prevalence of pTNM stage I cancers but a nearly fivefold…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 924 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.